CN104435362A - Traditional Chinese medicine compound for treating chronic pelvic inflammation - Google Patents
Traditional Chinese medicine compound for treating chronic pelvic inflammation Download PDFInfo
- Publication number
- CN104435362A CN104435362A CN201410789881.XA CN201410789881A CN104435362A CN 104435362 A CN104435362 A CN 104435362A CN 201410789881 A CN201410789881 A CN 201410789881A CN 104435362 A CN104435362 A CN 104435362A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- chronic pelvic
- medicine compound
- treatment
- inflammatory disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine and discloses a traditional Chinese medicine compound for treating chronic pelvic inflammation. The traditional Chinese medicine compound for treating chronic pelvic inflammation is prepared from the following Chinese herbs: motherwort herb, manchurian wildginger herb, prepared rhizome of adhesive rehmannia, chinese wolfberry, white peony root, Chinese angelica, sweet wormwood herb, yanhusuo, officinal magnolia bark, rangooncreeper fruit, common cnidium fruit and liquorice root. Clinical experiments verify that the traditional Chinese medicine compound for treating chronic pelvic inflammation has the advantages of short course of treatment, high total effective rate, remarkable improvement of clinical symptoms, small dosage of administration and treatment of both symptoms and root causes; besides, the chronic pelvic inflammation does not relapse after being cured.
Description
Technical field
The invention belongs to medical art, relate to a kind of Chinese medicine compound for the treatment of chronic pelvic inflammatory disease and preparation method thereof.
Background technology
Chronic pelvic inflammatory disease refers to female internal genital organs and surrounding connective tissue, pelvic peritoneal chronic inflammatory disease.Its main clinical manifestation is menoxenia, leucorrhoea grow in quantity, waist abdomen pain and infertile etc., as formed chronic adnexitis, then can touch lump.Symptom is visible: 1) chronic pelvic pain: the cicatricial adhesion that chronic inflammatory disease is formed and pelvic congestion, often cause hypogastric region falling inflation, pain and lumbosacral region to ache.Be everlasting after fatigue, sexual intercourse and aggravate before and after menstruation.2) infertile and ectopic pregnancy: fallopian tube adhesion is blocked can cause infertile and ectopic pregnancy.After acute pelvic inflammatory disease, infertile incidence rate is 20% ~ 30%.3) irregular menstruation: endometritis often has irregular menses; Pelvic congestion can cause menorrhagia; Menoxenia can be caused during ovarian function infringement.4) General Symptoms: how not obvious, only has low grade fever sometimes, and susceptible is tired.Because the course of disease time is longer, can there is neurasthenia symptom in some patients, as lassitude, whole body discomfort, insomnia etc.When patient's resistance difference, easily there is acute or subacute outbreak.Sign, if endometritis, uterus increases, tenderness; If salpingitis, then contact the thick fallopian tube of increasing in rope strip in one or both sides, uterus, and have mild tenderness.If hydrosalpinx or tubo-ovarian cyst, then touch Cystic lesions in pelvic cavity one or both sides, how limited activity is.If during inflammation of pelvic connective tissue, uterus is often in retroversioflexion, and limitation of activity or adhesion are fixed, and one or both sides, uterus have lamellar to thicken, tenderness, and uterosacral ligament often increases thick, hardening, has tenderness.
The traditional Chinese medical science is thought, the sick position of chronic pelvic inflammatory disease is at pelvic cavity, and its cause of disease is many by evil poison or damp and hot, through pudendum up and be against appoint, uterus, so that pathogen stay note or the stasis of blood stagnant or deficient in this portion, QI-blood circulation is obstructed, infringement pelvic tissue, or the course of disease with the passing of time, protracted course of disease, adhesion hypertrophy forms enclosed mass.Therefore blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis are the primary rules for the treatment of primary disease.Heat clearing away can be detoxified and dampness removing antiinflammatory, is conducive to eliminating evil removing toxic substances; Blood stasis dispelling can dissipating blood stasis, by reducing the permeability of inflammatory tissue blood capillary, is conducive to the absorption of inflammation.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine compound for the treatment of chronic pelvic inflammatory disease.
The object of the invention is to be achieved through the following technical solutions, the Chinese medicine compound of this treatment chronic pelvic inflammatory disease is made up of following Chinese crude drug:
Herba Leonuri, Herba Asari, Radix Rehmanniae Preparata, Cortex Lycii, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Herba Artemisiae Annuae, Rhizoma Corydalis, Cortex Magnoliae Officinalis, Fructus Quisqualis, Fructus Cnidii and Radix Glycyrrhizae.
Preferably, the Chinese medicine compound of this treatment chronic pelvic inflammatory disease is made up of the Chinese crude drug of following weight portion:
As one of optimal technical scheme, the Chinese medicine compound of this treatment chronic pelvic inflammatory disease is made up of the Chinese crude drug of following weight portion:
As another optimal technical scheme, the Chinese medicine compound of this treatment chronic pelvic inflammatory disease is made up of the Chinese crude drug of following weight portion:
Fang Zhong:
Herba Leonuri: promoting blood flow to regulate menstruation, inducing diuresis to remove edema.For menoxenia, dysmenorrhea, amenorrhea, lochiorrhea, edema oliguria; Acute nephritis edema.
Herba Asari: expelling wind and cold, understand things pain-stopping, warming the lung to resolve fluid-retention.For anemofrigid cold, headache, toothache, nasal obstruction nasal sinusitis, rheumatic arthralgia, phlegm retention is breathed with cough.
Radix Rehmanniae Preparata: nourishing YIN and supplementing blood, beneficial essence fills out marrow.For the hepatic and renal YIN deficiency, soreness of the waist and knees, osteopyrexia and fever, night sweat is passed out semen, and interior-heat is quenched one's thirst, blood deficiency and yellow complexion, severe palpitation, menoxenia, and metrostaxis is dizzy, tinnitus, early whitening of beard and hair
Cortex Lycii: removing heat from blood removes and steams, lung heat clearing pathogenic fire reducing.For deficiency of YIN hectic fever, hectic fever due to YIN-deficiency night sweat, cough due to lung-heat, spitting of blood, epistaxis, interior-heat is quenched one's thirst.
The Radix Paeoniae Alba: suppressing the hyperactive liver pain relieving, nourishing blood for regulating menstruation, astringing YIN to stop sweating.Dizzy for having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat.
Radix Angelicae Sinensis: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.For blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.Radix Angelicae Sinensis (processed with wine) promoting blood circulation to restore menstrual flow.For amenorrhea dysmenorrhea, rheumatic arthralgia, injury from falling down.
Herba Artemisiae Annuae: clearing away summer-heat, except steaming, preventing the attack (or recurrence) of malaria.For pathogenic summer-heat heating, fever due to yin deficiency, night fever abating at dawn, hectic fever due to YIN-deficiency consumptive fever, malaria cold and heat, jaundice due to damp-heat.
Rhizoma Corydalis: invigorate blood circulation, promoting the circulation of QI, pain relieving.For the breast side of body, epigastric pain, amenorrhea dysmenorrhea, postpartum stagnation, tumbling and swelling.
Fructus Quisqualis: killing insect and eliminating accumulation.For ascarid, enterobiasis, abdominal pain due to worm stagnation, infantile malnutrition.
Cortex Magnoliae Officinalis: dampness expectorant, the therapeutic method to keep the adverse QI flowing downwards is except full.For humidity hysteresis damaging the spleen and stomach, gastral cavity painful abdominal mass is vomited and diarrhoea, and stagnation of QI due to dyspepsia, abdominal distention constipation, phlegm retention is breathed with cough.
Fructus Cnidii: warming the kidney to invigorate YANG, dampness, dispels the wind, parasite killing.For sexual impotence, cold womb, cold-damp leukorrhagia, arthralgia chiefly caused by damp pathogen lumbago; External treatment vulval eczema, married woman's pudendal pruritus; Trichomonal vaginitis.
Radix Glycyrrhizae: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Chinese medicine compound of the present invention be by 12 taste Chinese crude drugs through scientific compatibility and through long-term clinical practice verify obtain.Long-term clinical experiment confirms: Chinese medicine ingredients of the present invention can be worked in coordination with mutually, attenuation gain; Play the merit of blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, dampness removing antiinflammatory altogether, and then play the effect for the treatment of chronic pelvic inflammatory disease.
The Chinese medicine compound that the present invention treats chronic pelvic inflammatory disease can make any one peroral dosage form, such as: tablet, pill, powder, capsule etc.Preferred capsule.
The preparation method that the present invention treats the Herbal compound capsule agent of chronic pelvic inflammatory disease is:
Take the Herba Leonuri of weight portion of the present invention, Herba Asari, Radix Rehmanniae Preparata, Cortex Lycii, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Herba Artemisiae Annuae, Rhizoma Corydalis, Cortex Magnoliae Officinalis, Fructus Quisqualis, Fructus Cnidii and Radix Glycyrrhizae, pulverized 100 mesh sieves, mix homogeneously, sterilizing, load No. 0 capsule.
Clinical experimental data
1. physical data
Receive undergoing chronic pelvic inflammation 170 example meeting inclusive criteria year November in January, 2013 to 2014.Be divided into two groups at random: treatment group 85 example, age 22-52 year, average 31.4 years old; The course of disease 3 months-5 years, average 20.8 months; Matched group 85 example, age 22-52 year, average 31.5 years old; The course of disease 3 months-5 years, average 21.2 months.Two groups of case ages, courses of disease etc. are through statistical procedures, and no significant difference (P > 0.05), has comparability.
2, diagnostic criteria
With reference to " tcm clinical practice disease Standardization of diagnosis and curative effect ": symptom: the conscious soreness of waist repeatedly, lower abdomen pendant pain, leucorrhoea grow in quantity, have abnormal flavour, and occasionally occur together heat; Gynecologial examination: body of uterus tenderness, bilateral attachment area thickens, and tenderness is obvious; B ultrasonic is pointed out: pelvic hydrops or inflammatory mass.
3, criterion of therapeutical effect
Effective: clinical symptom disappearance, gynecologial examination positive sign disappears, and B ultrasonic display inflammatory mass, pelvic hydrops disappear, and bilateral adnexa is normal; Effective: main clinic symptoms disappears or obviously alleviates, it is thinning that B ultrasonic display inflammatory mass reduces the adnexa thickened, and pelvic hydrops reduces or trend disappears; Invalid: main clinic symptoms and sign unchanged, B ultrasonic display inflammatory mass without change.
4, Therapeutic Method
Treatment group: adopt capsule prepared by the present invention, every day 3 times, each 4, continuously treatment 14 days.
Matched group: by specification or follow the doctor's advice oral cefalexin capsule and Metronidazole Tablet, continuously treatment 14 days.
5, therapeutic outcome
5.1 liang of group treatment comparitive study, see table 1.
Table 1 liang group treatment comparitive study
| Group | Number of cases | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 85 | 64(75.3％) | 21 | 0 | 100.0％ |
| Matched group | 85 | 22(25.9％) | 39 | 24 | 71.8％ |
Two groups are compared, and treatment group is obviously better than matched group, and difference has statistical significance (P < 0.01).
The improvement situation of 5.2 liang of group patient's main clinic symptoms and sign, see table 2.
The improvement situation of table 2 liang group symptom and sign
| Group | Number of cases | Lower abdominal pain | Lumbosacral aching pain | Profuse leukorrhea | Adnexa thickens |
| Treatment group | 85 | 80(94.1％) | 70(82.3％) | 62(72.9％) | 68(80.0％) |
| Matched group | 85 | 51(60.0％) | 39(45.9％) | 40(47.1％) | 52(61.2％) |
Two groups are compared, and symptom and sign are improved treatment group and be obviously better than matched group, and difference has statistical significance (P < 0.01).
After 6 months, the routine effective patient for the treatment of group 64 is paid a return visit, pay a return visit successfully 60 examples, have no recurrent cases.The routine effective patient of matched group 22, successfully pays a return visit 22 examples, has 10 example recurrences, relapse rate nearly 50%.
The display of above clinical trial results, the Chinese medicine compound that the present invention treats chronic pelvic inflammatory disease have short treating period, total effective rate high, significantly can improve clinical symptoms, the little and treating both the principal and secondary aspects of a disease of dosage, the advantage of non-relapse after healing.
Detailed description of the invention
EXAMPLE l
Take Herba Leonuri 30g, Herba Asari 14g, Radix Rehmanniae Preparata 20g, Cortex Lycii 15g, Radix Paeoniae Alba 10g, Radix Angelicae Sinensis 20g, Herba Artemisiae Annuae 10g, Rhizoma Corydalis 10g, Fructus Quisqualis 5g, Cortex Magnoliae Officinalis 10g, Fructus Cnidii 6g, Radix Glycyrrhizae 10g.Pulverize 100 mesh sieves, mix homogeneously, sterilizing, load No. 0 capsule.
Embodiment 2
Take Herba Leonuri 36g, Herba Asari 15g, Radix Rehmanniae Preparata 25g, Cortex Lycii 10g, Radix Paeoniae Alba 15g, Radix Angelicae Sinensis 15g, Herba Artemisiae Annuae 8g, Rhizoma Corydalis 12g, Fructus Quisqualis 10g, Cortex Magnoliae Officinalis 20g, Fructus Cnidii 10g, Radix Glycyrrhizae 15g.Pulverize 100 mesh sieves, mix homogeneously, sterilizing, load No. 0 capsule.
Embodiment 3
Take Herba Leonuri 26g, Herba Asari 6g, Radix Rehmanniae Preparata 16g, Cortex Lycii 6g, Radix Paeoniae Alba 10g, Radix Angelicae Sinensis 20g, Herba Artemisiae Annuae 6g, Rhizoma Corydalis 10g, Fructus Quisqualis 4g, Cortex Magnoliae Officinalis 16g, Fructus Cnidii 4g, Radix Glycyrrhizae 10g.Pulverize 100 mesh sieves, mix homogeneously, sterilizing, load No. 0 capsule.
The technology contents of the not detailed description of the present invention is known technology.
Claims (8)
1. treat a Chinese medicine compound for chronic pelvic inflammatory disease, it is characterized in that, the Chinese medicine compound of this treatment chronic pelvic inflammatory disease is made up of following Chinese medicine:
Herba Leonuri, Herba Asari, Radix Rehmanniae Preparata, Cortex Lycii, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Herba Artemisiae Annuae, Rhizoma Corydalis, Cortex Magnoliae Officinalis, Fructus Quisqualis, Fructus Cnidii and Radix Glycyrrhizae.
2. the Chinese medicine compound for the treatment of chronic pelvic inflammatory disease according to claim 1, is characterized in that, is made up of the Chinese crude drug of following weight portion:
3. the Chinese medicine compound for the treatment of chronic pelvic inflammatory disease according to claim 1, is characterized in that, is made up of the Chinese crude drug of following weight portion:
4. the Chinese medicine compound for the treatment of chronic pelvic inflammatory disease according to claim 1, is characterized in that, is made up of the Chinese crude drug of following weight portion:
5., according to the Chinese medicine compound of the arbitrary described treatment chronic pelvic inflammatory disease of claim 1-4, it is characterized in that, it can make any one peroral dosage form.
6. the Chinese medicine compound for the treatment of chronic pelvic inflammatory disease according to claim 5, is characterized in that, described peroral dosage form can be tablet, pill, powder or capsule.
7. the Chinese medicine compound for the treatment of chronic pelvic inflammatory disease according to claim 6, is characterized in that, described peroral dosage form is preferably capsule.
8. treat the Chinese medicine compound of chronic pelvic inflammatory disease according to claim 7, it is characterized in that, the preparation method of described capsule is:
Take the Herba Leonuri of weight portion of the present invention, Herba Asari, Radix Rehmanniae Preparata, Cortex Lycii, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Herba Artemisiae Annuae, Rhizoma Corydalis, Cortex Magnoliae Officinalis, Fructus Quisqualis, Fructus Cnidii and Radix Glycyrrhizae, pulverize 100 mesh sieves, mix homogeneously, sterilizing, filling capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410789881.XA CN104435362B (en) | 2014-12-18 | 2014-12-18 | A kind of Chinese medicine composition for the treatment of chronic pelvic inflammatory disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410789881.XA CN104435362B (en) | 2014-12-18 | 2014-12-18 | A kind of Chinese medicine composition for the treatment of chronic pelvic inflammatory disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104435362A true CN104435362A (en) | 2015-03-25 |
| CN104435362B CN104435362B (en) | 2015-08-19 |
Family
ID=52882623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410789881.XA Expired - Fee Related CN104435362B (en) | 2014-12-18 | 2014-12-18 | A kind of Chinese medicine composition for the treatment of chronic pelvic inflammatory disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435362B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311477A (en) * | 2015-12-07 | 2016-02-10 | 潘剑崎 | Traditional Chinese medicine for treating chronic pelvic inflammatory disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700291A (en) * | 2009-11-11 | 2010-05-05 | 陈坤 | Blood invigorating and menses regulating medicine for treating female infertility |
-
2014
- 2014-12-18 CN CN201410789881.XA patent/CN104435362B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700291A (en) * | 2009-11-11 | 2010-05-05 | 陈坤 | Blood invigorating and menses regulating medicine for treating female infertility |
Non-Patent Citations (2)
| Title |
|---|
| 梁晨耕: "中医药治疗慢性盆腔炎临床研究进展", 《江西中医药》 * |
| 韩惠兰: "慢性盆腔炎的中医治疗", 《中国全科医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311477A (en) * | 2015-12-07 | 2016-02-10 | 潘剑崎 | Traditional Chinese medicine for treating chronic pelvic inflammatory disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104435362B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940721B (en) | Medicine for treating chronic pelvic inflammation | |
| CN101700393B (en) | Traditional Chinese medicine composition for treating breast cancer | |
| CN103550695B (en) | Medicament for treating breast cancer | |
| CN105749037A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method and application thereof | |
| CN103393989B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN102631512B (en) | Traditional Chinese medicine composition for curing chronic colitis | |
| CN104043022A (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN103610804B (en) | Chinese medicinal soup decoction for treating chronic colitis | |
| CN104435362B (en) | A kind of Chinese medicine composition for the treatment of chronic pelvic inflammatory disease | |
| CN103656525A (en) | Traditional Chinese medicinal composition for treating dysmenorrhea | |
| CN103830591A (en) | Traditional Chinese medicine formula for treating stroke and post-traumatic brain syndrome and preparation method of traditional Chinese medicine | |
| CN101204494B (en) | Medicine for chronic enteritis | |
| CN103110809B (en) | Traditional Chinese medicine composition for treating diabetic constipation | |
| CN105749172A (en) | Medicament for treating gastric calculus and preparation thereof | |
| CN104306872A (en) | Traditional Chinese medicine for treating uterine fibroid | |
| CN103920104A (en) | Traditional Chinese medicinal composition for treating uterine bleeding syndrome of puerperal coagulated phlegm in uterus | |
| CN104306898A (en) | Orally taken traditional Chinese medicine for treating hysteromyoma | |
| CN104173952A (en) | Traditional Chinese medicine composition for treating benign ovarian tumor | |
| CN104352950A (en) | Traditional Chinese medicine composition for treating gynecological inflammation | |
| CN104258321A (en) | Traditional Chinese medicine for treating stroke induced hemiplegia | |
| CN104383417A (en) | Medicine for curing breast cancer | |
| CN103989885A (en) | Traditional Chinese medicine for treating chronic pelvic inflammation | |
| CN104127803A (en) | Traditional Chinese medicine preparation for treating qi-stagnation blood-stasis type amenorrhea | |
| CN104383093A (en) | Traditional Chinese medicine compound for treating haemorrhoids | |
| CN103127352B (en) | Chinese medicine composition for treating blood stasis type irregular menstruation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YU HUA Free format text: FORMER OWNER: LIU SHUQIN Effective date: 20150724 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yu Hua Inventor before: Fu Zhaowu |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FU ZHAOWU TO: YU HUA |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150724 Address after: 266041 Qingdao Licang Central Hospital, 49 Xingcheng Road, Licang District, Shandong, Qingdao Applicant after: Yu Hua Address before: 276017 No. 56 Industrial Street, Luozhuang District, Shandong, Linyi Applicant before: Liu Shuqin |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20151218 |
|
| EXPY | Termination of patent right or utility model |